Curis Lifesciences IPO Details
SME
Curis Lifesciences IPO opens for subscription on 07 Nov 2025 and closes on 11 Nov 2025. The IPO will be listed on NSE with the tentative listing date set for 14 Nov 2025.
Curis Lifesciences IPO price band has been fixed at ₹120 – ₹128 per share.The face value is ₹10 per share with a lot size of 1000.
Curis Lifesciences IPO total issue size comprises 21,50,000 shares (aggregating up to ₹27.52 Cr.). This includes a fresh issue of 21,50,000 shares (aggregating up to ₹27.52 Cr.). Pre-issue shareholding stands at 59,34,434, which will increase to 80,84,434 post-issue.
Curis Lifesciences IPO carries a ₹9 (7.03%) GMP, reflecting investor sentiment.
Curis Lifesciences IPO Lot Size : Individual Minimum is 2 lots (2,000 shares) amounting to ₹256,000. Individual Maximum is 2 lots (2,000 shares) amounting to ₹256,000. SHNI Minimum is 3 lots (3,000 shares) amounting to ₹384,000. SHNI Maximum is 7 lots (7,000 shares) amounting to ₹896,000. BHNI Minimum is 8 lots (8,000 shares) amounting to ₹1,024,000.
The Lead Managers for Curis Lifesciences IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Swastika Investmart Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is RS Wealth Management Pvt Ltd. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Curis Lifesciences Limited RHP.
Curis Lifesciences IPO Details
Curis Lifesciences IPO Subscription
Curis Lifesciences IPO Application Wise Breakup
Curis Lifesciences IPO Dates
- 07 Nov 2025Opening dateOpen
- 11 Nov 2025Closing dateClose
- 12 Nov 2025Allotment Date Allotment
- 13 Nov 2025Initiation of RefundsRefund
- 13 Nov 2025Credit of SharesCredit
- 14 Nov 2025Listing dateListing
Curis Lifesciences IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 2000 | ₹256,000 |
| Individual Maximum | 2 | 2000 | ₹256,000 |
| SHNI Minimum | 3 | 3000 | ₹384,000 |
| SHNI Maximum | 7 | 7000 | ₹896,000 |
| BHNI Minimum | 8 | 8000 | ₹1,024,000 |
Curis Lifesciences IPO Reservation
Promoter Holding
Curis Lifesciences IPO Valuations
Curis Lifesciences Financial Information
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 50.12 | 33.82 | 29.67 | 27.40 |
| Total Income | 36.91 | 35.89 | 36.39 | 23.76 |
| Profit After Tax | 5.30 | 5.03 | 1.85 | 0.49 |
| EBITDA | 8.89 | 8.41 | 3.25 | 3.58 |
| Net Worth | 15.53 | 5.97 | 0.95 | 0.90 |
| Reserves and Surplus | 9.59 | 5.47 | 0.45 | -1.40 |
| Total Borrowing | 16.16 | 17.09 | 16.19 | 17.62 |
| Amount in ₹ Crore | ||||
About Curis Lifesciences IPO
Established in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Curis Lifesciences specialises in the development, manufacturing, and distribution of a diverse range of pharmaceutical products, including:
- General pharmaceutical tablets and capsules
- Oral liquids
- External preparations
- Sterile ophthalmic ointments
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
The company offers various pharmaceutical formulations and products manufactured under contract.
They supply tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments.
As of June 30th, 2024, the company has 93 permanent employees.
Strength Of Curis Lifesciences IPO
- Experienced Promoters and Management Team.
- Wide range of Products.
- Strategic Location of Manufacturing Facility.
- Scalable Business Model.
- Quality assurance.
Risk Of Curis Lifesciences IPO
- Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
- As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
- Our business operations are subject to fluctuations in raw material prices.
- The company relies on a limited number of customers for its sales, and the loss of any major customer could adversely impact our revenue and profitability.
- The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.
- We depend on a limited number of States for a significant portion of our revenue from operations. The loss of any of our major customer in this States due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
- Our Company is dependent on a few countries. Loss of any of these large countries may affect our business operations.
- Our Company depends on some of our Products which contributes 100% of the total revenue of the company. The loss of any of this major Products due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
- The Statutory Auditor and the Peer Review Auditor of the company are not same.
- There are certain discrepancies/errors which have occurred in some of our corporate secretarial records relating to forms filed with the RoC and other provisions of Companies Act, 2013. Any penalty or action taken by any regulatory authorities in future.
Objectives Curis Lifesciences IPO
1. Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities
2. Capital Expenditure towards Construction of a Storage Facility
3. Pre-payment/Repayment of outstanding Secured Loans
4. Product Registrations in other countries
5. Funding our Working Capital Requirements
6. General Corporate Purposes
Company Contact Details
Curis Lifesciences Ltd.
PF-23, GIDC Sanand - II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Market Maker
Market Maker Reports
Curis Lifesciences IPO - FAQs
The Curis Lifesciences IPO is a SME public issue comprising 2150000 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹27.52 Cr.. The issue price has been fixed at ₹128 per equity share, and the minimum application size is 1000 shares.
The IPO opens for subscription on 07 Nov 2025, and closes on 11 Nov 2025.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE
As of now, the current GMP stands at ₹9 (7.03%).